ENSC

Ensysce Biosciences Inc

• TipRanks·09/29 13:01

  Ensysce Biosciences Updates Series C Preferred Stock Terms

• TipRanks·09/24 12:40

  Ensysce Biosciences submits Phase 2 protocol for CY200 to UK MHRA

• TipRanks·09/15 13:25

  Ensysce Biosciences advances CRPS program at Painweek 2026

• TipRanks·09/14 12:20

  Ensysce professor to speak at FDA public hearing on psychedelic drugs

• TipRanks·08/31 12:40

  Ensysce completes enrollment for final phase of PF614-MPAR-102 study

• Benzinga·08/31 12:35

  Ensysce Biosciences Completes Enrollment In Final Stage Of PF614-MPAR-102 Clinical Study

• TipRanks·08/25 22:01

  Ensysce Biosciences Gains Nasdaq Equity Compliance, Faces New Listing Hurdles

• TipRanks·08/24 21:28

  Ensysce Biosciences Seeks Extended Nasdaq Compliance Grace Period

• TipRanks·08/19 02:11

  Major Insider Move Sparks Fresh Buzz Around Ensysce Biosciences Stock

• Benzinga·08/13 17:05

  12 Health Care Stocks Moving In Thursday's Intraday Session

• NASDAQ·08/07 02:30

  Top Biotech Gainers: CELZ Soars On Patent News, BRVE Debuts Strong, IOVA Revenue Climbs 66%

• Benzinga·08/06 17:06

  12 Health Care Stocks Moving In Thursday's Intraday Session

• Benzinga·08/06 13:43

  Nasdaq Down 50 Points; US Foods Posts Upbeat Earnings

• TipRanks·08/06 12:55

  Ensysce Acquires Cy Biopharma, Expands Pain Therapy Portfolio

• Benzinga·08/06 12:06

  Ensysce Biosciences Completes Acquisition Of Cy Biopharma, Secures $17.1M Cash Financing And $21.5M Series C Preferred Stock Private Placement With Potential $38.6M Follow-On Tranche To Fund CY200 Development Through 2028